Review of topiramate for the treatment of epilepsy in elderly patients

BR Sommer1, HH Fenn21Department of Psychiatry, Stanford University School of Medicine, Stanford, California USA; 2Palo Alto VA Healthcare System, Acute Geropsychiatry Unit, Menlo Park Division, Menlo Park, California, USAAbstract: Individuals over 65 years of age experience the new onset of seizures...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	BR Sommer, HH Fenn
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Topiramate elderly epilepsy treatment cognition pharmacokinetics Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/503d42b1123840cc8c3c5bc4337bdb4f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:503d42b1123840cc8c3c5bc4337bdb4f
record_format	dspace
spelling	oai:doaj.org-article:503d42b1123840cc8c3c5bc4337bdb4f2021-12-02T06:58:43ZReview of topiramate for the treatment of epilepsy in elderly patients1178-1998https://doaj.org/article/503d42b1123840cc8c3c5bc4337bdb4f2010-04-01T00:00:00Zhttps://www.dovepress.com/review-of-topiramate-for-the-treatment-of-epilepsy-in-elderly-patients-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998BR Sommer1, HH Fenn21Department of Psychiatry, Stanford University School of Medicine, Stanford, California USA; 2Palo Alto VA Healthcare System, Acute Geropsychiatry Unit, Menlo Park Division, Menlo Park, California, USAAbstract: Individuals over 65 years of age experience the new onset of seizures at a prevalence rate of roughly twice that of younger adults. Differences in physiology, need of concomitant medications, and liability for cognitive deficits in this population, make the choice of anticonvulsant drugs especially important. This paper reviews topiramate (TPM), a treatment for many types of seizures, with the above risks in mind. In particular, we discuss efficacy and pharmacokinetics with emphasis on the older patient, and adverse events in both the younger and older adult. With most studies of TPM-induced cognitive deficits having been performed in younger adults and volunteers, we discuss the implications for the older adult. Even in studies of younger individuals, up to 50% discontinue TPM because of intolerable cognitive deficits. Most studies find specific declines in working memory and verbal fluency. In conclusion, we give recommendations for use of this antiepileptic drug in this population.Keywords: topiramate, elderly, epilepsy, treatment, cognition, pharmacokineticsBR SommerHH FennDove Medical PressarticleTopiramateelderlyepilepsytreatmentcognitionpharmacokineticsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 89-99 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Topiramate elderly epilepsy treatment cognition pharmacokinetics Geriatrics RC952-954.6
spellingShingle	Topiramate elderly epilepsy treatment cognition pharmacokinetics Geriatrics RC952-954.6 BR Sommer HH Fenn Review of topiramate for the treatment of epilepsy in elderly patients
description	BR Sommer1, HH Fenn21Department of Psychiatry, Stanford University School of Medicine, Stanford, California USA; 2Palo Alto VA Healthcare System, Acute Geropsychiatry Unit, Menlo Park Division, Menlo Park, California, USAAbstract: Individuals over 65 years of age experience the new onset of seizures at a prevalence rate of roughly twice that of younger adults. Differences in physiology, need of concomitant medications, and liability for cognitive deficits in this population, make the choice of anticonvulsant drugs especially important. This paper reviews topiramate (TPM), a treatment for many types of seizures, with the above risks in mind. In particular, we discuss efficacy and pharmacokinetics with emphasis on the older patient, and adverse events in both the younger and older adult. With most studies of TPM-induced cognitive deficits having been performed in younger adults and volunteers, we discuss the implications for the older adult. Even in studies of younger individuals, up to 50% discontinue TPM because of intolerable cognitive deficits. Most studies find specific declines in working memory and verbal fluency. In conclusion, we give recommendations for use of this antiepileptic drug in this population.Keywords: topiramate, elderly, epilepsy, treatment, cognition, pharmacokinetics
format	article
author	BR Sommer HH Fenn
author_facet	BR Sommer HH Fenn
author_sort	BR Sommer
title	Review of topiramate for the treatment of epilepsy in elderly patients
title_short	Review of topiramate for the treatment of epilepsy in elderly patients
title_full	Review of topiramate for the treatment of epilepsy in elderly patients
title_fullStr	Review of topiramate for the treatment of epilepsy in elderly patients
title_full_unstemmed	Review of topiramate for the treatment of epilepsy in elderly patients
title_sort	review of topiramate for the treatment of epilepsy in elderly patients
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/503d42b1123840cc8c3c5bc4337bdb4f
work_keys_str_mv	AT brsommer reviewoftopiramateforthetreatmentofepilepsyinelderlypatients AT hhfenn reviewoftopiramateforthetreatmentofepilepsyinelderlypatients
_version_	1718399630379581440

Review of topiramate for the treatment of epilepsy in elderly patients

Ejemplares similares